Sign in
Taking peoplePhase 3

Randomised Evaluation of COVID-19 Therapy

Key facts

Who runs it
University of Oxford
Where
Belgium, Estonia, France, Ghana, India, Indonesia, Italy, Nepal, Netherlands, Portugal, Romania, South Africa, Spain, Sweden, United Kingdom, and Vietnam74 sites in 16 countriesChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
70,000 people, planned
Started
19 Mar 2020
Expected to end
30 Sept 2038
Type of study
Interventional, 23 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Lopinavir-Ritonavir
  • Corticosteroid
  • Hydroxychloroquine
  • Azithromycin
  • Convalescent plasma
  • Tocilizumab
  • Immunoglobulin
  • Synthetic neutralising antibodies
  • Aspirin
  • Colchicine
  • Baricitinib
  • Anakinra
  • Dimethyl fumarate
  • High Dose Corticosteroid
  • Empagliflozin
  • Sotrovimab
  • Molnupiravir
  • Paxlovid
  • Baloxavir Marboxil
  • Oseltamivir
  • Corticosteroids (dexamethasone)
Record updated
21 April 2026

Who can take part

Age
0 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Other criteria

  • Eligibility Criteria (as per Protocol v28.0):
  • Patients are eligible for the study if all of the following are true:
  • (i) Hospitalised
  • (ii) Pneumonia syndrome
  • In general, pneumonia should be suspected when a patient presents with:
  • typical symptoms of a new respiratory tract infection (e.g. influenza-like illness with fever and muscle pain, or respiratory illness with cough and shortness of breath); and
  • objective evidence of acute lung disease (e.g. consolidation or ground-glass shadowing on X-ray or CT, hypoxia, or compatible clinical examination); and
  • alternative causes have been considered unlikely or excluded (e.g. heart failure); However, the diagnosis remains a clinical one based on the opinion of the managing doctor (the above criteria are just a guide); (iii) One of the following diagnoses:
  • Confirmed influenza A or B infection (including patients with SARS-CoV-2 co-infection)
  • Community-acquired pneumonia (CAP) with planned antibiotic treatment (excluding patients with suspected or confirmed SARS-CoV-2, influenza, active pulmonary tuberculosis or Pneumocystis jirovecii pneumonia); (iv) No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial; Patients with suspected or confirmed active pulmonary tuberculosis or Pneumocystis jirovecii pneumonia (also known as PCP or PJP) are excluded from the CAP comparison, as these infections are caused by specific organisms with distinct pathologies, and so are not usually categorised as CAP. Eligibility for the CAP comparison also requires planned antibiotic treatment, so patients being treated solely for fungal or viral pneumonia are not eligible; Patients with SARS-CoV-2 and influenza co-infection are eligible, but would be excluded from certain comparisons if the attending clinician believes that there is a specific contra-indication to one of the active drug treatment arms (see Protocol Appendix 2, Appendix 3 for children, and Appendix 4 for pregnant and breastfeeding women), or that the patient should definitely be receiving one of the active drug treatment arms then that arm will not be available for randomisation for that patient. For patients who lack capacity, an advanced directive or behaviour that clearly indicates that they would not wish to participate in the trial would be considered sufficient reason to exclude them from the trial; Patients who have been previously recruited into RECOVERY are eligible to be recruited again as long as their previous randomisation was >6 months ago. Patients will not be recruited into the same randomised comparison (e.g. sotrovimab vs. usual care) on more than one occasion, regardless of how far apart they occur; In some locations, children (aged <18 years) will not be recruited, to comply with local and national regulatory approvals (see Appendix 6); Note: the eligibility criteria has changed from COVID-19 to pneumonia (Influenza \& CAP). For detailed information about previous eligibility criteria please see the previous Protocol's on the study website: https://www.recoverytrial.net/uk/for-site-staff/site-set-up-1/regulatory-documents

This trial has no sites in United States.

It has sites in 16 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

RECOVERY is a randomised trial of treatments to prevent death in patients hospitalised with pneumonia.

Read full original descriptionShow less

The treatments being investigated are:

COVID-19: Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Colchicine, IV Immunoglobulin (children only), Convalescent plasma, Casirivimab+Imdevimab, Tocilizumab, Aspirin, Baricitinib, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid or Anakinra (children only)

Influenza: Baloxavir marboxil, Oseltamivir, Corticosteroids (dexamethasone)

Community-acquired pneumonia: Corticosteroids (dexamethasone)

The 23 groups in the trial

  • Standard CareNo study treatment, for comparison

    Patient receives usual hospital care

  • CorticosteroidsExisting treatment, for comparison

    First (main) randomisation part A (COVID-19) \[This arm is now closed to recruitment\]

    Treatment: Corticosteroid

  • HydroxychloroquineExisting treatment, for comparison

    First (main) randomisation part A (COVID-19) \[This arm is now closed to recruitment\]

  • Lopinavir-RitonavirExisting treatment, for comparison

    First (main) randomisation part A (COVID-19) \[This arm is now closed to recruitment\]

  • AzithromycinExisting treatment, for comparison

    First (main) randomisation part A (COVID-19) \[This arm is now closed to recruitment\]

  • Convalescent plasmaExisting treatment, for comparison

    First (main) randomisation part B (COVID-19) \[This arm is now closed to recruitment\]

  • TocilizumabExisting treatment, for comparison

    Participants with progressive COVID-19 (as evidenced by hypoxia and an inflammatory state) may undergo randomisation between Tocilizumab and no additional treatment. (Children with COVID-19 pneumonia are not eligible for this comparison). \[This arm is now closed to recruitment\]

  • Intravenous ImmunoglobulinExisting treatment, for comparison

    First (main) randomisation part A (children only) \[This arm is now closed to recruitment\]

    Treatment: Immunoglobulin

  • Synthetic neutralising antibodiesExisting treatment, for comparison

    First (main) randomisation part B (COVID-19) \[This arm is now closed to recruitment\]

  • AspirinExisting treatment, for comparison

    First (main) randomisation part C (COVID-19) \[This arm is now closed to recruitment\]

  • ColchicineExisting treatment, for comparison

    First (main) randomisation part A (COVID-19) \[This arm is now closed to recruitment\]

  • BaricitinibExisting treatment, for comparison

    First (main) randomisation part D (COVID-19) \[This arm is now closed to recruitment\]

  • AnakinraExisting treatment, for comparison

    Randomisation for children only with PIMS-TS (Children with COVID-19 pneumonia are not eligible for this comparison). \[This arm is now closed to recruitment\]

  • Dimethyl fumarateExisting treatment, for comparison

    First (main) randomisation part A (COVID-19) (UK adults only; early phase assessment) \[This arm is now closed to recruitment\]

  • High Dose CorticosteroidsExisting treatment, for comparison

    First (main) randomisation part E (COVID-19) \[This arm is now closed to recruitment\]

    Treatment: High Dose Corticosteroid

  • EmpagliflozinExisting treatment, for comparison

    First (main) randomisation part F (COVID-19) \[This arm is now closed to recruitment\]

  • SotrovimabExisting treatment, for comparison

    First (main) randomisation part J (COVID-19) \[This arm is now closed to recruitment\]

  • MolnupiravirExisting treatment, for comparison

    First (main) randomisation part K (COVID-19) \[This arm is now closed to recruitment\]

  • PaxlovidExisting treatment, for comparison

    First (main) randomisation part L (COVID-19) \[This arm is now closed to recruitment\]

  • Baloxavir marboxilExisting treatment, for comparison

    Randomisation part G (influenza)

  • OseltamivirExisting treatment, for comparison

    Randomisation part H (influenza)

  • Corticosteroids (dexamethasone) (influenza arm)Existing treatment, for comparison

    Randomisation part I (influenza)

    Treatment: Corticosteroids (dexamethasone)

  • Corticosteroids (dexamethasone) (community-acquired pneumonia arm)Existing treatment, for comparison

    Randomisation part M (community-acquired pneumonia)

    Treatment: Corticosteroids (dexamethasone)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Publications
Record updated
21 April 2026